Developing molecular markers to select the anti-cancer therapies in metastatic colorectal cancer

ABSTRACT: Interventions: Oxialiplatin-based therapies (FOLFOX, CapeOX), Irinotecan-based therapies (FOLFIRI, IFL, IRIS), Molecular targeting therapies (Bevacizumab, Cetuximab) Mutational analyses of various genes Primary outcome(s): Association between the response rate of anti-cancer drug therapies and genetic alterations Study Design: Parallel Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2619748 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR